ISPOR 2020: do we have sufficient health economics data for digital therapeutics? Economic evaluation abstract highlights
ISPOR 2020 – inside the second plenary: moving from population health to 'precision population health'
ISPOR 2020: do managed entry agreements for ATMPs exist in Germany? Curative and genetic therapies abstract highlights
ISPOR 2020 – inside the first plenary: both necessity and science give rise to invention
ISPOR 2020: how may we enable faster access to multi-indication orphan products? Rare disease and orphan drug abstract highlights
Events, ISPOR, Health technology assessment, Medical devices, pharmaceuticals and vaccines, Methodology, Real-world evidence, Stakeholder engagement
[ON DEMAND] Improving efficiency in health technology assessment with advanced software: a panel discussion
Estimating the opportunity–cost-based cost–effectiveness threshold: a peek behind the podcast
Look behind the lecture: can biosimilars improve patient access in countries with restricted resources?